EDIT vs KMB · rev $32.3M vs P/E 19, rev $20.06B
Editas Medicine Inc (EDIT) versus Kimberly-Clark Corporation (KMB) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Kimberly-Clark Corporation (KMB) is a household & personal products company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported KMB revenue for 2024-12-31 was $20.06B. Net income was $2.58B. Revenue was down 1.8% from 2023-12-31 to 2024-12-31. KMB currently screens at market cap $32.88B and trailing P/E 19.2.
EDIT currently screens at market cap $375.2M. KMB currently screens at market cap $32.88B and trailing P/E 19.2.
Not investment advice. Open the EDIT and KMB stock pages for the full models.
Not investment advice.